Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
urogenital diseases | D000091642 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
MYFEMBREE | Myovant Sciences | N-214846 RX | 2021-05-26 | 1 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ORGOVYX | Myovant Sciences | N-214621 RX | 2020-12-18 | 1 products, RLD, RS |
Expiration | Code | ||
---|---|---|---|
ESTRADIOL / NORETHINDRONE ACETATE / RELUGOLIX, MYFEMBREE, MYOVANT SCIENCES | |||
2026-01-27 | M-289 | ||
2025-12-18 | NCE | ||
2025-08-05 | I-898 | ||
2024-05-26 | NP | ||
RELUGOLIX, ORGOVYX, SUMITOMO PHARMA | |||
2025-12-18 | NCE |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Estradiol / Norethindrone Acetate / Relugolix, Myfembree, Myovant Sciences | |||
11793812 | 2038-05-03 | U-2360 | |
11033551 | 2037-09-29 | U-3129 | |
11795178 | 2033-09-27 | DS, DP | |
7300935 | 2025-01-28 | DP | |
8058280 | 2025-01-28 | DS, DP | |
9346822 | 2024-02-17 | U-3129 | |
Relugolix, Orgovyx, Sumitomo Pharma | |||
10449191 | 2037-09-29 | U-3020 | |
10786501 | 2037-09-29 | U-3020 | |
11583526 | 2037-09-29 | U-3020 | |
10350170 | 2036-02-25 | DP | |
8735401 | 2024-02-04 | U-3019 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Menorrhagia | D008595 | EFO_0003945 | N92.0 | — | — | 4 | 1 | — | 5 |
Leiomyoma | D007889 | — | D25 | — | — | 4 | 1 | — | 5 |
Pelvic pain | D017699 | — | — | — | — | — | 1 | — | 1 |
Metrorrhagia | D008796 | — | N92.1 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hemorrhage | D006470 | MP_0001914 | R58 | — | — | 4 | — | — | 4 |
Myofibroma | D047708 | — | — | — | — | 4 | — | — | 4 |
Endometriosis | D004715 | EFO_0001065 | N80 | — | — | 3 | — | — | 3 |
Prostatic neoplasms | D011471 | — | C61 | — | 2 | 1 | — | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Adenocarcinoma | D000230 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
Drug common name | Relugolix |
INN | relugolix |
Description | Relugolix, sold under the brand names Orgovyx and Relumina among others, is a gonadotropin-releasing hormone antagonist (GnRH receptor antagonist) medication which is used in the treatment of prostate cancer in men and uterine fibroids in women. It is taken by mouth.
|
Classification | Small molecule |
Drug class | gonadotropin releasing hormone (GnRH) receptor antagonists (nonpeptide) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CONC(=O)Nc1ccc(-c2sc3c(c2CN(C)C)c(=O)n(-c2ccc(OC)nn2)c(=O)n3Cc2c(F)cccc2F)cc1 |
PDB | — |
CAS-ID | 737789-87-6 |
RxCUI | — |
ChEMBL ID | CHEMBL1800159 |
ChEBI ID | — |
PubChem CID | 10348973 |
DrugBank | DB11853 |
UNII ID | P76B05O5V6 (ChemIDplus, GSRS) |